Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › BNT162b2

BNT162b2

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of BNT162b2

17 trials tracked of BNT162b2: 8 in phase 3 or 4 and 6 with published results. The most-cited published study has 339 citations.

17Trials tracked
8Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 1 Phase 3 7 Phase 2 6 Other / NA 3
  1. Phase 3 To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. Completed · 339 cited
  2. Phase 3 Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals Completed · 240 cited
  3. Phase 3 To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older Completed · 54 cited
  4. Phase 4 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults Completed · 30 cited
  5. Phase 3 Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 Completed · 28 cited
  6. Phase 3 Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age Completed · 25 cited
Show 11 more trials
  1. Phase 3 A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants Completed
  2. Phase 3 A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults Completed
  3. Phase 2 Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants Completed
  4. Phase 2 Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years Completed
  5. Phase 2 COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) Completed
  6. Phase 2 A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects Completed
  7. Phase 2 Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines Completed
  8. Phase 2 A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults Completed
  9. N/A Special Investigation of COMIRNATY in the Population With Underlying Diseases Completed
  10. N/A Drug Use Investigation of COMIRNATY Intramuscular Injection Completed
  11. N/A A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
BNT162b2 vaccination shows no significant increase in stroke risk in meta-analysis
Neurology Meta-analysis
BNT162b2 vaccination shows no significant increase in stroke risk in meta-analysis COVID vaccine not linked to higher stroke risk, analysis finds
This meta-analysis, involving several million vaccinated individuals, found no statistically significant increase in stroke risk following B…
A large analysis finds no increased stroke risk after the Pfizer COVID vaccine, offering reassurance for millions.
Aug 29, 2026
mRNA-1283 and BNT162b2 COVID-19 vaccines show protective effectiveness in adults aged 65 and older
Infectious Disease Cohort
mRNA-1283 and BNT162b2 COVID-19 vaccines show protective effectiveness in adults aged 65 and older New Vaccine Cuts Hospital Risk for Seniors by Nearly 60%
This observational cohort study in U.S. adults aged >=65 years found mRNA-1283 had higher adjusted vaccine effectiveness (aVE) for COVID-19…
A new 2025–2026 COVID vaccine slashes hospital risk for seniors by nearly 60%, offering stronger protection when aging immune systems need i…
medRxiv Apr 19, 2026